Home » NasVax, SciGen to Collaborate on Hepatitis Vaccine
NasVax, SciGen to Collaborate on Hepatitis Vaccine
Israel’s NasVax has signed an agreement with Singapore’s SciGen to develop and commercialize a nasally delivered vaccine against hepatitis B.
The vaccine was created by Israeli pharmaceutical company Biotechnology General, according to Israeli business daily Globes.
Under the agreement, Phase I and IIa trials of the vaccine will be conducted in Israel and will begin in 2008.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May